2008-10-06 03:02:02 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/research/836884/hong_kong_pharmace) has announced the addition of the "Hong Kong Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
BMI's Hong Kong Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Hong Kong's pharmaceuticals and healthcare industry.
Hong Kong's US$866mn pharmaceutical market is
characterised by low generic drug penetration, a preference for branded goods, a sizeable traditional Chinese medicine (TCM) segment, and the presence of counterfeits. Growth of the market over the next five years will be driven by new product launches and an increase in healthcare funding. Expansion will be moderated by patent expiries and greater uptake of generic drugs. BMI is forecasting CAGR of 6.33% through to 2012, when the value of the pharmaceutical market will have reached US$1.18bn.
In BMI's opinion, the importance of branding, liberal advertising and modern promotional activities in the Special Administrative Region (SAR) cannot be underestimated. A 47-country poll conducted by market research firm ACNielsen in 2007 found that Hong Kong residents were the most likely to buy a certain non-prescription medicine because it was a brand they always purchased. This degree of product loyalty means that barriers to entry are high, and that franchise management is of paramount importance to established players.
Healthcare uptake is projected to rise, in part due to the expansion of the population, but mainly because the proportion of older people in the population is rising. This is due to the fact that older individuals have more chronic diseases such as osteoporosis and Alzheimer's disease. It is estimated that over the period 2004-2033, total health expenditure will increase by 55% at an annual growth rate of 1.5%, solely due to demographic effects (including population growth and a greater proportion of older people within the population).
US drugmakers have expressed concerns about the lengthy approval procedures for new pharmaceuticals, which effectively shorten the period of patent protection by 6 months. Moreover, US are worried that the Hong Kong Department of Health will continue to issue marketing authorisations for patent infringing pharmaceuticals.
Tuberculosis has a significant impact in Hong Kong, seeing 6,000 cases, which result in 270 deaths each year on average. Compared to other countries at a similar stage of development, these figures are extremely poor. Accordingly, the Department of Health is looking at ways to reduce the burden of disease.
Key Topics Covered:
- Hong-Kong Political SWOT
- Hong-Kong Economic SWOT
- Hong-Kong Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Hong Kong - Market Summary
- Industry Trends And Developments
- Pharmaceutical Industry
- Foreign Industry Developments
- Industry Forecast Scenario
- Key Growth Factors
- Patented Drug Market Forecast
- Generic Drug Market Forecasts
- OTC Market Forecast
- Export/Import Forecasts
- Key Risks To BMI's Forecast Scenario
- Competitive Landscape
- Company Profiles
Companies Mentioned:
- GlaxoSmithKline
- Pfizer
- Sanofi-Aventis
- Merck & Co
- Novartis
- Local Pharmaceutical Companies
- Wuyi International Pharmaceutical
- CK Life Sciences
- South Asia Pharmamedic Ltd
- C&Y Pharmaceutical Investment Holding
-Vida Laboratories
For more information visit
www.researchandmarkets.com/research/836884/hong_kong_pharmace
Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com 
